JP2023541048A5 - - Google Patents

Info

Publication number
JP2023541048A5
JP2023541048A5 JP2023515751A JP2023515751A JP2023541048A5 JP 2023541048 A5 JP2023541048 A5 JP 2023541048A5 JP 2023515751 A JP2023515751 A JP 2023515751A JP 2023515751 A JP2023515751 A JP 2023515751A JP 2023541048 A5 JP2023541048 A5 JP 2023541048A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical product
product according
weeks
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541048A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/049785 external-priority patent/WO2022056209A1/en
Publication of JP2023541048A publication Critical patent/JP2023541048A/ja
Publication of JP2023541048A5 publication Critical patent/JP2023541048A5/ja
Pending legal-status Critical Current

Links

JP2023515751A 2020-09-10 2021-09-10 パーキンソン病の処置 Pending JP2023541048A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063076916P 2020-09-10 2020-09-10
US202063076915P 2020-09-10 2020-09-10
US202063076913P 2020-09-10 2020-09-10
US63/076,915 2020-09-10
US63/076,916 2020-09-10
US63/076,913 2020-09-10
US202163158191P 2021-03-08 2021-03-08
US63/158,191 2021-03-08
PCT/US2021/049785 WO2022056209A1 (en) 2020-09-10 2021-09-10 Treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
JP2023541048A JP2023541048A (ja) 2023-09-27
JP2023541048A5 true JP2023541048A5 (enExample) 2026-08-07

Family

ID=80629905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515751A Pending JP2023541048A (ja) 2020-09-10 2021-09-10 パーキンソン病の処置

Country Status (10)

Country Link
US (2) US12084491B2 (enExample)
EP (1) EP4211162A4 (enExample)
JP (1) JP2023541048A (enExample)
KR (1) KR20230086674A (enExample)
AU (1) AU2021338781A1 (enExample)
CR (1) CR20230121A (enExample)
IL (1) IL301039A (enExample)
MX (1) MX2023002851A (enExample)
TW (1) TW202227131A (enExample)
WO (1) WO2022056209A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20240279316A1 (en) * 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
CN117409969B (zh) * 2023-11-13 2026-04-03 深圳市臻络科技有限公司 帕金森病运动功能评估方法、装置及电子设备

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7981058B2 (en) 2004-03-12 2011-07-19 The Trustees Of Dartmouth College Intelligent wearable monitor systems and methods
US20060122472A1 (en) 2004-09-28 2006-06-08 Pullman Seth L System and method for clinically assessing motor function
US8702629B2 (en) 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
JP5251270B2 (ja) 2008-06-04 2013-07-31 三菱化学株式会社 パーキンソン病の評価装置
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US20100076348A1 (en) 2008-09-23 2010-03-25 Apdm, Inc Complete integrated system for continuous monitoring and analysis of movement disorders
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN101963919A (zh) 2009-07-24 2011-02-02 鸿富锦精密工业（深圳）有限公司 进程管理系统
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9924899B2 (en) 2013-09-09 2018-03-27 Alexis Pracar Intelligent progression monitoring, tracking, and management of parkinson's disease
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP6595490B2 (ja) 2014-02-04 2019-10-23 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター 身体固定センサを使用してパーキンソン病の診断または予後を提供する方法およびシステム
US20180126158A1 (en) 2016-08-22 2018-05-10 Lyriq, Llc Systems and Methods for Functional Restoration and Rehabilitation of Posture, Gait and Movement
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
EP3833435B1 (en) 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
KR20230154249A (ko) 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료

Similar Documents

Publication Publication Date Title
Mirtaleb et al. Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Crosby et al. Amantadine in Parkinson's disease
JP2015096532A (ja) パーキンソン病緩和のためのラサギリン
JP6145778B2 (ja) 特発性炎症性筋疾患の予防又は治療剤
JP2007510736A (ja) 多発性硬化症に付随する症状を治療するためのデルタ−９−ｔｈｃ組成物及び方法
JP2017510607A5 (enExample)
JPH0227327B2 (enExample)
Hall et al. Rapid deterioration in patients with parkinsonism following tryptophan‐pyridoxine administration
Gilligan et al. Amantadine hydrochloride in the treatment of Parkinson's disease
RU2202345C2 (ru) Новое применение креатина
HERZ et al. Hepatolenticular degeneration: analysis of dyskinetic phenomena; relation of degree of hepatic damage to course of the disease; nervous disorders in ordinary disease of the liver
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
Baker Treatment of paralysis agitans with vitamin B6 (pyridoxine hydrochloride)
Sorbera et al. ERIGO: a possible strategy to treat orthostatic hypotension in progressive supranuclear palsy? A feasibility study
JP2021088571A (ja) 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
RU2213565C1 (ru) Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
SU1382478A1 (ru) Способ лечени экстрапирамидных заболеваний
PAIN Effects of End-Range Mobilization Technique on Pain and Disability in Patients With Adhesive Capsulitis-a Quasi-Experimental Study
O'Hare A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication
CN108498496B (zh) 亮蓝g在制备急性co中毒的治疗药物中的应用
Volden Peripheral neuropathy: a side effect of sulphones
Kaufmann et al. Durability of effect and safety of open-label ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor, for symptomatic treatment of neurogenic orthostatic hypotension
Linton Isonicotinic acid hydrazide: some sensory disturbances during therapy
EL-Said Emergent management of Guillain-Barré syndrome.